Loading
A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., now recruiting.
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07441174 by InxMed (Shanghai) Co., Ltd., with 92 participants planned, started 2026-02-28 and due to reach its primary completion in 2031-02-28. Interventions recorded: IN10018 in combination with RNK08954.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ranok Therapeutics (Hangzhou), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ranok Therapeutics (Hangzhou) and the tag pipeline.
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IN10018 and the tag pipeline.
Shares IN10018 and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/